Feline Diabetes Mellitus: Insulin Resistance, Remission Potential, and Evidence-Based Clinical Decision-Making

Feline diabetes mellitus (FDM) is a common endocrine disorder characterised by persistent hyperglycaemia and impaired glucose metabolism. Unlike canine diabetes, which is primarily insulin-deficient, most diabetic cats display features of insulin resistance combined with relative insulin deficiency, resembling type-2 diabetes in humans¹. Understanding these pathophysiological mechanisms is critical for diagnosis, monitoring, and management decisions. 

Pathophysiology and Clinical Implications 

Insulin resistance in cats can result from obesity, chronic glucotoxicity, and, in some cases, hypersomatotropism (HST), a condition of excessive growth hormone secretion^2,4. HST is recognised as a clinically significant cause of insulin-resistant diabetes in cats. Evidence shows that treating HST can markedly improve glycaemic control and occasionally lead to remission⁴. 

Decision Point: Considering Etiology 

If a diabetic cat demonstrates poor glycaemic control despite appropriate insulin therapy, then consider evaluating underlying insulin resistance causes such as HST, obesity, or concurrent endocrinopathies^2,4. 

Diagnosis 

Diagnosis of FDM should rely on persistent hyperglycaemia and glucosuria in combination with compatible clinical signs¹. Single elevated glucose readings can be confounded by stress-induced hyperglycaemia. Serial measurements, home monitoring, or continuous glucose monitoring may improve diagnostic accuracy¹. 

Decision Point: Confirming True Diabetes 

If initial hyperglycaemia is inconsistent or not accompanied by glucosuria or clinical signs, then repeat assessment or home-based monitoring should precede insulin therapy to prevent misdiagnosis¹. 

Insulin Therapy and Management 

Insulin remains the first-line therapy for most cats¹. Management should be individualised, considering the cat's clinical condition, comorbidities, and caregiver capability. Dose adjustments should be based on trends in glucose measurements rather than isolated readings to reduce hypoglycaemia risk¹. 

Decision Point: Avoiding Over-Aggressive Titration 

If glycemic control is suboptimal, but the cat is clinically stable, then reassess administration technique, diet, and underlying resistance factors before escalating insulin doses¹. 

Remission Potential 

Remission is defined as sustained normoglycaemia without exogenous insulin¹. Cats are more likely to achieve remission when diagnosis is early, and glucose toxicity is promptly managed². However, even in remission, underlying insulin resistance may persist, warranting ongoing monitoring³. 

Decision Point: Framing Remission 

If early, stable glycaemic control is achieved, then remission can be pursued as a realistic outcome; if hyperglycaemia has been prolonged or insulin resistance is marked, then maintaining stable control becomes the primary goal^2,3. 

 Monitoring and Follow-Up 

Monitoring should emphasise trends and variability rather than isolated measurements. Structured home glucose monitoring, periodic fructosamine testing, and, where available, CGM can guide therapy. Persistent abnormalities should prompt investigation for underlying causes or comorbidities¹. 

Decision Point: Normoglycaemia During Monitoring 

If glucose values remain within target ranges, then cautious insulin adjustment may be considered, but ongoing monitoring is essential to detect relapse or hidden insulin resistance³. 

 Clinical Takeaways  

Feline diabetes mellitus typically involves a combination of insulin resistance and relative insulin deficiency, resembling type‑2 diabetes in humans. Single hyperglycaemia readings are unreliable due to stress-induced fluctuations; therefore, trend-based monitoring using serial glucose measurements or structured home/continuous monitoring is essential for accurate diagnosis and treatment adjustment. While remission is possible, it does not guarantee normal insulin sensitivity, and cats in remission require ongoing monitoring to detect relapse or persistent metabolic dysfunction. Poor glycaemic control despite appropriate insulin therapy and compliance should prompt evaluation for underlying causes of insulin resistance, including hypersomatotropism and other endocrine disorders, as addressing these conditions can significantly influence clinical outcomes. 

References  

1. Taylor S, Cannon M, Church D, Fleeman L, Fracassi F, Gilor C, et al. iCatCare consensus guidelines on the diagnosis and management of diabetes mellitus in cats. J Feline Med Surg. 2025.  

2. Patra S, McMillan CJ, Snead ER, Warren AL, Cosford K, Chelikani PK. Feline diabetes is associated with deficits in markers of insulin signalling in peripheral tissues. Int J Mol Sci. 2024;25(23):13195.  

3. Gottlieb S, Rand JS, Ishioka K, Dias DA, Boughton BA, Roessner U, Ramadan Z, Anderson ST. Measures of insulin sensitivity, leptin, and adiponectin concentrations in cats in diabetic remission compared to healthy control cats. Frontiers in Veterinary Science. 2022 Jul 29;9:905929. 

4. Van Bokhorst KL, Galac S, Kooistra HS, Valtolina C, Fracassi F, Rosenberg D, Meij BP. Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats. Journal of Veterinary Internal Medicine. 2021 Mar;35(2):834-42.